# BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

> **NCT02417129** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 2 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Rituximab
- **DRUG:** BI 695500

## Key facts

- **NCT ID:** NCT02417129
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02417129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02417129, "BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02417129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*